Literature DB >> 12927511

Medicinal chemistry of target family-directed masterkeys.

Gerhard Müller1.   

Abstract

The majority of pharmaceutically relevant drug targets cluster into densely populated target families, thus offering a novel approach that complements the currently favoured screening paradigm in medicinal chemistry. This approach uses a privileged structure concept whereby molecular masterkeys are developed that account for a target family wide structural or functional commonality. Numerous lead compounds, based on multipurpose privileged structures, can be generated that address a variety of targets from a gene family of interest, irrespective of therapeutic area. Several different interpretations of the privileged structure concept will be highlighted, with a strong emphasis on the most stringent application: the optimization of a molecular masterkey for a distinct target family of interest.

Mesh:

Year:  2003        PMID: 12927511     DOI: 10.1016/s1359-6446(03)02781-8

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  31 in total

1.  Defining scaffold geometries for interacting with proteins: geometrical classification of secondary structure linking regions.

Authors:  Tran T Tran; Christina Kulis; Steven M Long; Darryn Bryant; Peter Adams; Mark L Smythe
Journal:  J Comput Aided Mol Des       Date:  2010-09-23       Impact factor: 3.686

2.  Pharmacophore model for bile acids recognition by the FPR receptor.

Authors:  Cristina Ferrari; Antonio Macchiarulo; Gabriele Costantino; Roberto Pellicciari
Journal:  J Comput Aided Mol Des       Date:  2006-09-14       Impact factor: 3.686

3.  Topological side-chain classification of beta-turns: ideal motifs for peptidomimetic development.

Authors:  Tran Trung Tran; Jim McKie; Wim D F Meutermans; Gregory T Bourne; Peter R Andrews; Mark L Smythe
Journal:  J Comput Aided Mol Des       Date:  2005-11-23       Impact factor: 3.686

4.  A myosin V inhibitor based on privileged chemical scaffolds.

Authors:  Kabirul Islam; Harvey F Chin; Adrian O Olivares; Lauren P Saunders; Enrique M De La Cruz; Tarun M Kapoor
Journal:  Angew Chem Int Ed Engl       Date:  2010-11-02       Impact factor: 15.336

Review 5.  Combinatorial chemistry: oh what a decade or two can do.

Authors:  Walter H Moos; Clarence R Hurt; Guillermo A Morales
Journal:  Mol Divers       Date:  2009-03-03       Impact factor: 2.943

6.  Structural and Activity Profile Relationships Between Drug Scaffolds.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  AAPS J       Date:  2015-02-20       Impact factor: 4.009

7.  Structure-Promiscuity Relationship Puzzles-Extensively Assayed Analogs with Large Differences in Target Annotations.

Authors:  Ye Hu; Swarit Jasial; Erik Gilberg; Jürgen Bajorath
Journal:  AAPS J       Date:  2017-03-06       Impact factor: 4.009

8.  Is scaffold hopping a reliable indicator for the ability of computational methods to identify structurally diverse active compounds?

Authors:  Dilyana Dimova; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2017-06-16       Impact factor: 3.686

9.  Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Authors:  Douglas R Davies; Bjorn Mamat; Olafur T Magnusson; Jeff Christensen; Magnus H Haraldsson; Rama Mishra; Brian Pease; Erik Hansen; Jasbir Singh; David Zembower; Hidong Kim; Alex S Kiselyov; Alex B Burgin; Mark E Gurney; Lance J Stewart
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

10.  Chemical substructures that enrich for biological activity.

Authors:  Justin Klekota; Frederick P Roth
Journal:  Bioinformatics       Date:  2008-09-10       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.